We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

64 hedge funds and large institutions have $107M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 66 → 64 (-2)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

24% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 21

40% less capital invested

Capital invested by funds: $178M → $107M (-$71.1M)

Holders
64
Holders Change
-2
Holders Change %
-3.03%
% of All Funds
1.01%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
16
Reduced
21
Closed
14
Calls
$54K
Puts
–
Net Calls
+$54K
Net Calls Change
+$43K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$692K
2
CC
Corton Capital
Ontario, Canada
+$262K
3
MA
MCF Advisors
Kentucky
+$259K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$213K
5
DU
Delphia (USA)
Ontario, Canada
+$184K

Top Sellers

Rank Fund Capital Flow
1
N
Natixis
France
-$11.6M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.42M
3
PVI
Pura Vida Investments
New York
-$612K
4
GCP
GSA Capital Partners
United Kingdom
-$577K
5
BlackRock
BlackRock
New York
-$379K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$42M +$28K +6,213 +0.1%
PCM
2
Pentwater Capital Management
Florida
$22.3M – – –
BlackRock
3
BlackRock
New York
$11.1M -$379K -84,036 -3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$6.48M -$26.6K -5,891 -0.4%
ACM
5
Aisling Capital Management
New York
$4.67M – – –
Millennium Management
6
Millennium Management
New York
$3.74M -$279K -61,928 -7%
State Street
7
State Street
Massachusetts
$2.38M -$55.7K -12,359 -2%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.25M +$56.1K +12,433 +3%
JP Morgan Chase
9
JP Morgan Chase
New York
$1.43M +$94.2K +20,894 +7%
RSCM
10
Rock Springs Capital Management
Maryland
$1.3M – – –
ASN
11
Advisory Services Network
Georgia
$1.16M – – –
Northern Trust
12
Northern Trust
Illinois
$1.07M -$56.4K -12,504 -5%
Charles Schwab
13
Charles Schwab
California
$987K +$37.6K +8,329 +4%
Renaissance Technologies
14
Renaissance Technologies
New York
$838K +$692K +153,400 +457%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$648K +$213K +47,233 +49%
N
16
Nuveen
North Carolina
$463K +$6.17K +1,368 +1%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$457K -$8.07K -1,790 -2%
CC
18
Corton Capital
Ontario, Canada
$260K +$262K +58,027 New
MA
19
MCF Advisors
Kentucky
$257K +$259K +57,469 New
Goldman Sachs
20
Goldman Sachs
New York
$253K -$96.7K -21,455 -28%
Morgan Stanley
21
Morgan Stanley
New York
$236K +$35.4K +7,857 +18%
JIC
22
Johnson Investment Counsel
Ohio
$209K – – –
William Blair & Company
23
William Blair & Company
Illinois
$203K -$16.9K -3,746 -8%
AI
24
Atom Investors
Texas
$183K +$71.6K +15,887 +64%
DU
25
Delphia (USA)
Ontario, Canada
$182K +$184K +40,733 New
1
2 3 4

PSTX Hedge Fund Activity: Q1 2022 in Review

64 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2022, worth a combined $107M — down 40% from $178M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of PSTX and 12 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 16 added.

The largest buyer was Renaissance Technologies, adding an estimated $692K. The largest seller was Natixis, exiting entirely with an estimated $11.6M sold.

  • 64 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2022, down from 66 in Q4 2021.
  • Funds reported $107M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2022, down 40% quarter-over-quarter.
  • 12 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -2 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $692K added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2022 was Natixis, an estimated $11.6M sold.

Based on aggregated 13F filings for Q1 2022.